Codexis, Inc.

Codexis discovers, develops, and sells enzymes and proteins through two segments: Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services, including screening and protein engineering. The company also has a technology platform called CodeEvolver for developing biocatalysts. Codexis collaborates with Nestlé Health Science on CDX-7108 for exocrine pancreatic insufficiency treatment. Products are sold to pharmaceutical manufacturers through direct sales in the US and Europe.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

1.6 USD

Potential

-100%

Strengths

Price to book ratio (2.01) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0

Codexis, Inc.

Overview

Strengths

Weaknesses

Key Financial Data